The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.
The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.
The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
The expected gross proceeds are more than double what the firm proposed as its original goal for the offering when it filed plans to list its shares in September.
The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.
The company said it plans to list its stock on the Nasdaq under the ticker symbol GH.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.